Medline FDA warning hits 200+ complaints; Abbott cuts outlook
Supply Chain Pulse — 2026-04-17
Medline just received an FDA warning letter after more than 200 complaints about its heart procedure syringes—a stark reminder that even established suppliers aren't immune to quality control failures that can disrupt your OR schedules. Meanwhile, Abbott slashed its profit forecast following the Exact Sciences acquisition, and Lilly is betting big on cancer care with a $300M CrossBridge Bio deal. It's shaping up to be a week where supply chain leaders need to stay extra vigilant about vendor stability and have backup plans ready.
Quick Hits
- AMGA partners with Talkiatry to expand psychiatric care referrals (Modern Healthcare)
- Health systems betting big on concierge medicine programs (Modern Healthcare)
- City of Hope expands national cancer network to Chicago (Modern Healthcare)
- Hackensack Meridian opens healthcare hub at transit center (Modern Healthcare)
- Federation of American Hospitals focuses on transparency fight under new CEO (Modern Healthcare)
Medline receives FDA warning letter on heart procedure syringes
The FDA issued a warning letter to Medline following more than 200 complaints about its heart procedure syringes—a significant quality control red flag for one of healthcare's largest suppliers. This could signal potential supply disruptions for cardiac procedures, and procurement teams should immediately assess their exposure to affected Medline products and identify alternative suppliers.
Abbott cuts profit forecast in wake of Exact Sciences deal
Abbott slashed its full-year adjusted earnings forecast to $5.38-$5.58 per share following its Exact Sciences acquisition, signaling integration challenges ahead. For supply chain leaders, this profit pressure at a major diagnostics supplier could translate to pricing volatility or potential service disruptions as Abbott works through the merger.
Lilly to acquire CrossBridge Bio for up to $300M
Eli Lilly is acquiring CrossBridge Bio for up to $300M to secure CBB-120, a dual-payload antibody-drug conjugate for cancer treatment. This aggressive oncology play signals continued consolidation in specialty pharmaceuticals, which could impact drug pricing and availability for health systems managing cancer care programs.
Source: Pharmaceutical Business Review
AI chatbots give misleading medical advice 50% of the time
A new study found AI chatbots provide incorrect medical advice half the time, raising serious concerns as clinicians increasingly turn to these tools for decision support. Supply chain leaders should be cautious about AI-powered procurement and inventory management systems that lack proper clinical validation.
Healthcare companies seek $693M in IPOs as pace picks up
U.S. healthcare companies have raised $2.37 billion from IPOs in 2026, with another $693M in the pipeline from biotechs and medical device makers. This funding surge could accelerate innovation but also create market volatility as emerging companies compete for market share against established suppliers.
HeartFlow sues Cleerly over patent infringement allegations
HeartFlow filed a patent infringement lawsuit against cardiac imaging competitor Cleerly, alleging its CEO used insider knowledge to build a competing platform. Legal battles between AI-powered diagnostic companies could disrupt product roadmaps and create uncertainty for health systems evaluating these emerging technologies.
Source: Medical Device Network
Employers see promise as price transparency policy matures
Employer groups report that hospital price transparency rules are finally delivering meaningful insights into healthcare costs and insurance negotiations. This growing transparency could pressure health systems to justify their pricing to employer-sponsored health plans, potentially affecting contract negotiations.
eMed raises $200M in major telehealth funding round
Telehealth platform eMed secured $200M in one of 2026's largest digital health funding rounds, signaling continued investor confidence in remote care delivery. This capital influx could accelerate telehealth adoption and create new opportunities for supply chain partnerships in home-based care products.
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe